Sugi Predict

Sugi Predict / Compounds / SCHEMBL1073201

SCHEMBL1073201

SCHEMBL1073201

N#Cc1ccccc1S(=O)(=O)N1CCC(CCNc2ccc3cc2CCc2cncc(c2)Nc2ncc(Cl)c(n2)N3)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 8/20 0.42
▸ JAK2 O60674 2/20 0.38
▸ JAK1 P23458 2/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ HTR2A P28223 3/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ NPY5R Q15761 1/20 0.34
▸ BCHE P06276 2/20 0.33
▸ ACHE P22303 2/20 0.33
▸ ATM Q13315 1/20 0.33
▸ HTR1A P08908 2/20 0.32
▸ DRD2 P14416 2/20 0.32
▸ HTR7 P34969 2/20 0.32
▸ HTR6 P50406 2/20 0.32
▸ GPR6 P46095 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1074311 0.95 GPR6 (0.39) ALKJAK2JAK1TYK2JAK3
SCHEMBL1073997 0.90 ALK (0.42) ALKJAK2JAK1TYK2JAK3
SCHEMBL4367864 0.88 ALK (0.41) ALKJAK2JAK1TYK2JAK3
SCHEMBL1075078 0.87 ALK (0.52) ALKJAK2JAK1TYK2JAK3
Trifluoroacetic Acid SCHEMBL4364682 0.86 ALK (0.39) ALKJAK2JAK1TYK2JAK3
Trifluoroacetic Acid SCHEMBL4369601 0.86 ALK (0.38) ALKJAK2JAK1TYK2JAK3
SCHEMBL1076200 0.85 ALK (0.48) ALKJAK2JAK1TYK2JAK3
SCHEMBL4356880 0.84 ALK (0.43) ALKJAK2JAK1TYK2JAK3
SCHEMBL13622657 0.82 ALK (0.48) ALKJAK2JAK1TYK2JAK3
SCHEMBL4352494 0.81 JAK2 (0.47) ALKJAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US claimed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 — — EP claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US claimed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 — — WO claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK ALK 3/4885JAK2 1/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.